EUVIMEDEUVIMED entdecken
Open Access

How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL

Lori Muffly iD, Emily C Liang iD, J Gregory Dolan iD, Michael A Pulsipher iD

Blood · 2024

DOI: 10.1182/blood.2023023699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Lori Muffly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, High-Throughput Nucleotide Sequencing, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) evaluation by multiparameter flow cytometry (MFC) or quantitative polymerase chain reaction methods is an established standard of care for assessing risk of relapse before or after hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL). Next-generation sequencing (NGS)–MRD has emerged as a highly effective approach that allows for the detection of lymphoblasts at a level of <1 in 106 nucleated cells, increasing sensitivity of ALL detection by 2 to 3 logs. Early studies have shown superior results compared with MFC and suggest that NGS-MRD may allow for the determination of patients in whom reduced toxicity transplant preparative approaches could be deployed without sacrificing outcomes. Many centers/study groups have implemented immune modulation approaches based on MRD measurements that have resulted in improved outcomes. Challenges remain with NGS-MRD, because it is not commercially available in many countries, and interpretation of results can be complex. Through patient case review, discussion of relevant studies, and detailed expert opinion, we share our approach to NGS-MRD testing before and after HCT in pediatric and adult ALL. Improved pre-HCT risk classification and post-HCT monitoring for relapse in bone marrow and less invasive peripheral blood monitoring by NGS-MRD may lead to alternative approaches to prevent relapse in patients undergoing this challenging procedure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultChildFemaleHumansMaleRecurrence

Autor:innen und Institutionen

  • Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, Intermountain Primary Children's Hospital, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT.
  • Division of Pediatric Hematology and Oncology, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT.

ORCID-Profile: Lori Muffly, Emily C Liang, J Gregory Dolan, Michael A Pulsipher

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Muffly, L., Liang, E. C., Dolan, J. G., & Pulsipher, M. A. (2024). How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood. https://doi.org/10.1182/blood.2023023699

Vancouver

Muffly L, Liang EC, Dolan JG, Pulsipher MA. How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood. 2024. doi:10.1182/blood.2023023699

BibTeX
@article{Muffly2024,
  author = {Muffly, Lori and Liang, Emily C and Dolan, J Gregory and Pulsipher, Michael A},
  title = {How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023023699}
}
Kostenlos starten →